GSK seeks to abandon 'white pill and Western markets' strategy

GlaxoSmithKline is to pull out of certain health areas in the next stage of Andrew Witty's transformation of the drug group.

Note: The news article featured above is provided for information and general interest and is not an investment recommendation.